Creative Medical Technology Holdings Inc. 2025年度报告

(Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-53500 85012(Zip Code) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectivenessof its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of theregistrant included in the filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ As of March 20, 2026, there were 3,696,668 shares of the registrant’s common stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the registrant’s definitive proxy statement for the registrant’s 2025 Annual Meeting of Stockholders which will be filedwith the Commission no later than 120 days after the registrant’s fiscal year ended December 31, 2025, are incorporated by reference DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS The information contained in this Annual Report on Form 10-K contains certain forward-looking statements. All statements other thanstatements of historical facts contained or incorporated by reference in this Annual Report, including statements regarding our futurefinancial position, business strategy and plans and objectives of management for future operations, are forward-looking statements.The words “anticipate,” “believe,” “estimate,” “will,” “may,” “future,” “plan,” “intend” and “expect” and similar expressions generallyidentify forward-looking statements. These forward-looking statements are not guarantees and are subject to known and unknownrisks, uncertainties and assumptions that may cause our actual results, levels of activity, performance, or achievements to be materiallydifferent from any future results, levels of activity, performance or achievements expressed or implied by such forward-lookingstatements. Although we believe that our plans, intentions and expectations reflected in the forward-looking statements are reasonable, we cannot be sure that they will be achieved. Particular uncertainties that could cause our actual results to be materially different than ANNUAL REPORT ON FORM 10-KFor the Year Ended December 31, 2025 Table of Contents ItemDescription Part II 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities346.Selected Financial Data377.Management’s Discussion and Analysis of Financial Condition and Results of Operations377A.Quantitative and Qualitative Disclosures About Market Risk448.Financial Statements and Supplementary DataF-19.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure459A.Controls and Procedures459B.Other Information45 Part IIIDirectors, Executive Officers and Corporate Governance 10. 11.Executive Compensation 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters13.Certain Relationships and Related Transactions and Director Independence 14.Principal Accountant Fees and Services Part IV Table of Contents Item 1. Business Overview We are a commercial stage biotechnology company dedicat